Amgen to Acquire Celgene’s Otezla® for US$13.4 B
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 9 (Table of Contents)
Published: 3 Sep-2019
DOI: 10.3833/pdr.v2019.i9.2452 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In light of concerns expressed by the US Federal Trade Commission, Bristol-Myers Squibb has agreed to divest Celgene’s psoriasis drug, Otezla® (apremilast), to Amgen in exchange for US$13...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS